Germany Atopic Dermatitis Drugs Market Size & Outlook
Germany atopic dermatitis drugs market, 2018-2030 (US$M)
Related Markets
Germany atopic dermatitis drugs market highlights
- The Germany atopic dermatitis drugs market generated a revenue of USD 939.1 million in 2024 and is expected to reach USD 1,593.3 million by 2030.
- The Germany market is expected to grow at a CAGR of 9% from 2025 to 2030.
- In terms of segment, biologics was the largest revenue generating drug class in 2024.
- PDE4 Inhibitors is the most lucrative drug class segment registering the fastest growth during the forecast period.
Atopic dermatitis drugs market data book summary
| Market revenue in 2024 | USD 939.1 million |
| Market revenue in 2030 | USD 1,593.3 million |
| Growth rate | 9% (CAGR from 2025 to 2030) |
| Largest segment | Biologics |
| Fastest growing segment | PDE4 Inhibitors |
| Historical data | 2018 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Corticosteroids, Calcineurin Inhibitors, PDE4 Inhibitors, Biologics |
| Key market players worldwide | Pfizer Inc, Sanofi SA, AbbVie Inc, Galderma Group AG Registered Shares, Eli Lilly and Co, Regeneron Pharmaceuticals Inc, Otsuka Holdings Co Ltd, Novartis AG ADR, Incyte Corp, LEO Pharma |
Other key industry trends
- In terms of revenue, Germany accounted for 5.3% of the global atopic dermatitis drugs market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, Germany atopic dermatitis drugs market is projected to lead the regional market in terms of revenue in 2030.
- France is the fastest growing regional market in Europe and is projected to reach USD 1,226.3 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Atopic Dermatitis Drugs Market Scope
Atopic Dermatitis Drugs Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Germany atopic dermatitis drugs market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to atopic dermatitis drugs market will help companies and investors design strategic landscapes.
Biologics was the largest segment with a revenue share of 44.99% in 2024. Horizon Databook has segmented the Germany atopic dermatitis drugs market based on corticosteroids, calcineurin inhibitors, pde4 inhibitors, biologics covering the revenue growth of each sub-segment from 2018 to 2030.
Germany has a strong healthcare system, which covers 90% of the population under mandatory health insurance. Thereby, access to atopic dermatitis treatment in this country is relatively easier. Increasing R&D in the country on atopic dermatitis to develop novel treatments is accelerating its market.
For instance, as per British Journal of Dermatology, in 2020, noninterventional study TREAT Germany, a German atopic eczema registry, studied the effectiveness of treatment regimes in patients. New entrant biologic drug Dupilumab demonstrated clinical effectiveness in these studies.
Local presence of key players, such as Bayer, is expected to boost the country’s market. For instance, Evotec AG entered into a collaboration with Almirall for developing durable and potent treatments for dermatological conditions such as atopic dermatitis.
Reasons to subscribe to Germany atopic dermatitis drugs market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Germany atopic dermatitis drugs market databook
-
Our clientele includes a mix of atopic dermatitis drugs market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Germany atopic dermatitis drugs market , including forecasts for subscribers. This country databook contains high-level insights into Germany atopic dermatitis drugs market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Germany atopic dermatitis drugs market size, by drug class, 2018-2030 (US$M)
Germany Atopic Dermatitis Drugs Market Outlook Share, 2024 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
